Scientific Conferences

Presenting the Latest Discoveries in Research

Fred Hutch researchers present their work at many scientific conferences each year. The spectrum of cancer research topics range from from population science and prevention to cancer biology, hematology, clinical studies, to survivorship and advocacy. Our Media Relations team assists journalists who are seeking additional information, interviews or expert referrals.

ASCO conference from above
More than 30,000 physicians, researchers and healthcare professionals from more than 100 countries attend the 52nd Annual ASCO Meeting in Chicago. Photo by ASCO/David Eulitt

Upcoming Conferences

Dec 9
Dec 9

American Society of Hematology Annual Meeting

This is a multi-day event, please click for details
Fred Hutch scientists will present the latest findings on transplantation, cell therapies, precision medicine and more at the 65th Annual American Society of Hematology meeting. The ASH meeting features scientific abstracts highlighting updates on the most critical topics in hematology.
Location San Diego, California
Host American Society of Hematology

Your search for "" did not match any of our events. Please try another event term or combination of terms and filters.

Past Conferences


American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is an international network of oncology professionals.  The ASCO annual meeting offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.

ASCO 2019


Caring for Every Patient, Learning from Every Patient
May 31–June 4, 2019
Chicago, IL

Highlights included oral presentations on:

Other highlights included poster presentations on topics such as complications of bone marrow transplantation, quality of life in survivors of young-adult cancers, first-line immunotherapy in advanced kidney cancer, the impact of national cooperative group studies, and more.

Read our media tip sheet

ASCO 2018


Delivering Discoveries: Expanding the Research of Precision Medicine
June 1–June 5, 2018
Chicago, IL

Topics included:

  • Factors affecting patient outcomes after a CAR T-cell therapy
  • Durable outcomes from immunotherapy and a paradigm shift in Merkel cell carcinoma
  • Colorectal cancer care, cost and survival in western Washington state vs. British Columbia
  • Disparities in cancer clinical trials participation
  • Cost-effectiveness and affordability of drugs and genetic testing for non-small cell lung cancer
  • Cancer biosimilars

American Association for Cancer Research (AACR)

The American Association for Cancer Research (AACR) Annual Meeting program covers the latest discoveries across the spectrum of cancer research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions all over the world.

AACR 2019


Integrative Cancer Science — Global Impact — Individualized Patient Care
March 29-April 3, 2019
Atlanta, GA

Highlights included presentations on immunotherapy for solid tumors and updates on progress toward targeting the molecular drivers of lung, breast and prostate cancers.

Read our media tip sheet

All Fred Hutch presentations

Download speaker highlights

AACR 2018


Driving Innovative Cancer Science to Patient Care
April 14-18, 2018
Atlanta, GA

This meeting put a spotlight on next-gen approaches to transgenic T-cell receptor, or TCR, immunotherapy, in which patients’ T cells are genetically engineered to produce a naturally occurring, cancer-targeting receptor called a TCR.

Presentation topics included:

  • Next-generation T-cell therapies
  • Big-data for cancer Research
  • Racial disparities in prostate cancer
  • Cancer survivorship
  • Precision medicine

American Society of Hematology (ASH)

The American Society of Hematology (ASH) is the worlds' largest professional society serving both clinicians and scientists around the world who are working  to conquer blood diseases. The ASH annual meeting provides is an educational experience providing the opportunity to review thousands of scientific abstracts on the hottest topics in hematology.

ASH 2019


Fred Hutch researchers presented talks and posters on a number of topics including CAR T-cell therapies, gene therapies, precision oncology, immune repair and transplantation 

Transplantation physician-scientist Dr. Stephanie Lee became the new president of ASH, T-cell therapy pioneer Dr. Philip Greenberg gave the E. Donnall Thomas Lecture, and Dr. Andrew Cowan presented the latest on a new BCMA, or B-cell maturation antigen, CAR T-cell therapy for multiple myeloma. 

Read our media tip sheet

All Fred Hutch presentations

ASH 2018


December 1-4, 2018
San Diego

The meeting featured the E. Donnall Thomas Lecture and Prize, created in 1992 and named after the late Nobel laureate who pioneered bone marrow transplantation at Fred Hutch and served as a past ASH president. The lecture and prize recognizes pioneering research achievements in hematology that have represented a paradigm shift or significant discovery in the field.

Other highligts included talks on cellular immunotherapies for leukemia, lymphoma and myeloma; gene therapy for hemoglobinopathies; hematopoietic cell transplantation; immune regeneration; and precision medicine for blood cancers.

Transplantation & Cellular Therapy (TCTM)

The Transplantation & Cellular Therapy Meetings are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). The meeting features the E. Donnall Thomas Lecture, named after the late Nobel laureate who pioneered bone marrow transplantation at Fred Hutch. The lecture recognizes an eminent physician or scientist who has contributed meritoriously to the advancement of knowledge in blood and marrow transplantation.

TCTM 2019


February 20-24, 2019
Houston, Texas

Highlighted Abstracts

Wednesday, February 20

Advances in Graft Engineering for GVHD Reduction
Marie Bleakley, M.D., Ph.D.

Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier, M.D., M.Sc.

20 Years of Experience with Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting (Poster)
Noa Granot, M.D.

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study (Poster)
Mohamed Sorror, M.D., M.Sc.

Factors Associated with Toxicity of CD19 CAR-T Cell Immunotherapy
Cameron J. Turtle, MBBS, Ph.D.

Mortimer M. Bortin Lecture - Treatment of Chronic Graft‐versus‐host Disease—Progress to Date and Challenges Ahead
Paul Martin, M.D.

Creation of Personalized Patient Care Plans for HCT Survivors
Scott Baker, M.D., M.S.

Oral Brincidofovir Decreased HHV-6 Viremia in Hematopoietic Cell Transplant Recipients: Results from the Suppress Study (Poster)
Joshua Hill, M.D.

Whole Blood RNA-Seq Differentiates Hematopoietic Cell Transplant Recipients with Upper Versus Lower Respiratory Tract Rhinovirus Infection (Poster)
Alpana Waghmare, M.D.

Quantifying Cytomegalovirus-Specific T Cell Responses Prior to Hospital Discharge Allows Risk Stratification for Late Viral Reactivation after Allogenic Hematopoietic Cell Transplantation (Poster)
Michael Boeckh, M.D., Ph.D.

CMV Viral Load after Peripheral Blood Stem Cell Transplantation (PBSCT) and Posttransplant High-Dose Cyclophosphamide (PTCy)
Masumi Ueda, M.D., M.A.

Related Stories

All news
What’s new in breast cancer research? San Antonio conference goes hybrid for 2021 Hutch researchers look at overdiagnosis, cardiotoxicity of chemotherapy, cost of a new surveillance method and more December 14, 2021
Gimme shelter: CRISPR hides healthy cells from leukemia drug In mouse study, gene-edited cells stay safe as immunotherapy attacks cancer December 9, 2019
Try, try again: Can a 2nd dose of CAR T cells succeed when the first fails? First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options December 7, 2019
Failed Alzheimer’s drug boosts CAR T-cell therapy Engineered immune cells get a helping hand in new clinical trial for multiple myeloma patients September 26, 2019

Contact Our Media Relations Team

We are always available to help. Please include your deadline if your request is urgent.